Can you maintain GLP-1 weight loss without medication
Glucagon-like peptide-1 and its class b G protein-coupled receptors: A long march to therapeutic successes
However, as the maintenance dose is achieved by dose escalation to mitigate gastrointestinal side effects, some weight loss was observed with liraglutide during the 5-week period
Instead, clinicians should acknowledge this risk and consider individualized risk-benefit strategies when prescribing GLP-1 RAs, particularly for patients with pre-existing ocular manifestations and must inform patients regarding possible ocular hazards while advocating for regular retinal examinations and assessments of visual acuity
Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment
The most recognised adverse effects are gastrointestinal disturbances, such as nausea, vomiting, constipation, gastritis, and diarrhoea